Impact of optimal lipid value achievement between 2005 and 2009 in patients with mixed dyslipidaemia on cardiovascular event rates

International Journal of Clinical Practice

Volumn 65, Issue 4, 2011, Pages 425-435

  Cziraky, M J ^a   Tan, H ^a   Bullano, M F ^b   Yu, J ^a   Schiebinger, R ^b   Willey, Vincent J ^c  

^a HEALTHCORE INC   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REFERENCE VALUE;

AGED; CEREBROVASCULAR DISORDERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIPIDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PERIPHERAL ARTERIAL DISEASE; RETROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 79952768544     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02643.x     Document Type: Article

References (28)

1. NCEP Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
2. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-32.
3. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67.
4. Waters DD, Brotons C, Chiang CW et al. Lipid Treatment Assessement Project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009; 120: 28-34.
5. Mosca L, Banka CL, Benjamin EJ et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007; 115: 1481-501.
6. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010; 33(Suppl. 1): S11-61.
7. Briel M, Ferreira-Gonzalez I, You JJ et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009; 338: b92 doi:10.1136/bmj.b92.
8. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary hear disease. Am J Cardiol 2006; 98: 1363-8. (Pubitemid 44666646)
9. Nichols GA, Ambegaonkar BM, Sazonov V, Brown JB. Frequency of obtaining National Cholesterol Education Program Adult Treatment Panel III goals for all major serum lipoproteins after initiation of lipid altering therapy. Am J Cardiol 2009; 104: 1689-94.
10. Simvastatin (Zocor®) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc., 2008.
11. Lovastatin (Mevacor) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc., 2008.
12. Atorvastatin (Lipitor) [prescribing information]. New York, NY: Parke-Davis, Division of Pfizer, Inc., 2009.
13. Fluvastatin (Lescol, Lescol XL) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp., 2006.
14. Pravastatin (Pravachol) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Co., 2007.
15. Rosuvastatin (Crestor) [prescribing information]. Wilmington, DE: Astra Zeneca Pharmaceuticals LP., 2009.
16. Stacy TA, Egger A. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. J Manag Care Pharm 2006; 12: 745-51. (Pubitemid 47394435)
17. Sarawate CA, Cziraky MJ, Stanek EJ, Willey VJ, Corbelli JC, Charland SL. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed? Clin Ther 2007; 29: 196-209.
18. Mosca L, Merz NB, Blumenthal RS et al. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation 2005; 111: 488-93. (Pubitemid 40204434)
19. Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin 2007; 23: 553-63. (Pubitemid 46456903)
20. Charland SL, Cziraky MJ, Quimbo R et al. Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events. J Clin Lipidol 2008; 2: 243-353.
21. Sharma M, Ansari MT, Abou-Setta AM et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009; 151: 622-30.
22. The Accord Study Group. Effects of combination lipid therapy in Type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-74.
23. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992; 85: 37-45.
24. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21-7.
25. Scott R, O'Brien R, Fulcher G et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009; 32: 493-8.
26. Jun M, Foote C, Lu J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375: 1875-84.
27. Villines TC, Stanek EJ, Devine PJ et al. The ARBITER 6-HALTS Trial (arterial biology for the investigation of the treatment effects of reducing cholesterol 6 - HDL and LDL treatment strategies in atherosclerosis. J Am Coll Cardiol 2010; 55: 2721-6.
28. Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intimamedia thickness. N Engl J Med 2009; 361: 2113-22.